Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

被引：0

作者：

Usmani, Saad Z. ^{[1
]}

Facon, Thierry ^{[2
]}

Hungria, Vania ^{[3
]}

Bahlis, Nizar J. ^{[4
]}

Venner, Christopher P. ^{[5
,6
]}

Braunstein, Marc ^{[7
]}

Pour, Ludek ^{[8
]}

Marti, Josep ^{[9
]}

Basu, Supratik ^{[10
,11
]}

Cohen, Yael C. ^{[12
]}

Matsumoto, Morio ^{[13
]}

Suzuki, Kenshi ^{[14
]}

Hulin, Cyrille ^{[15
]}

Grosicki, Sebastian ^{[16
]}

Legiec, Wojciech ^{[17
]}

Beksac, Meral ^{[18
]}

Maiolino, Angelo ^{[19
]}

Liu, Weiping ^{[20
]}

Wang, Jianping ^{[21
]}

Krevvata, Maria ^{[21
]}

Lopez-Masi, Lorena ^{[22
]}

Carey, Jodi ^{[21
]}

Rowe, Melissa ^{[23
]}

Carson, Robin ^{[21
]}

Zweegman, Sonja ^{[24
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Clin Med Sao Germano, Sao Paulo, Brazil

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[6] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[7] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Hosp Univ Mutua Terrassa, Terrassa, Spain

[10] Royal Wolverhampton NHS Trust, Wolverhampton, England

[11] Univ Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, England

[12] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[13] Natl Hosp Org, Dept Hematol, Shibukawa Med Ctr, Gunma, Japan

[14] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[15] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[16] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[17] St John Dukla Oncol Ctr Lublin Land, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland

[18] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[19] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[20] Janssen Res & Dev, Shanghai, Peoples R China

[21] Janssen Res & Dev LLC, Spring House, PA USA

[22] Janssen Res & Dev LLC, Raritan, NJ USA

[23] Janssen Res & Dev LLC, High Wycombe, Bucks, England

[24] Vrije Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-63

引用

页码：S288 / S289

页数：2

共 50 条

[1] Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial (Feb, 10.1038/s41591-024-03485-7, 2025)
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep M.
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Takamatsu, Hiroyuki
Perrot, Aurore
Turgut, Mehmet
Ahmadi, Tahamtan
Liu, Weiping
Wang, Jianping
Chastain, Katherine
Vermeulen, Jessica
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
NATURE MEDICINE, 2025, : 1195 - 1202
[2] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[3] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[4] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[5] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
[6] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu
Shinsuke Iida
Hirohiko Shibayama
Kazuhiro Shibayama
Hiroshi Yamazaki
Kenshi Suzuki
International Journal of Hematology, 2020, 111 : 692 - 701
[7] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2014, 124 (21)
[8] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[9] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[10] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Twumasi-Ankrah, Philip
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
BLOOD, 2021, 137 (26) : 3616 - 3628

← 1 2 3 4 5 →